

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/524,945 – Conf. #3129
		Filing Date	February 16, 2005
		First Named Inventor	Farhad Parhami
		Art Unit	1633
		Examiner Name	Maria Gomez Leavitt
Sheet	1	of	1
		Attorney Docket Number	58086-241892

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US- 6,080,779	6/27/2000	Gasper et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	B1					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	Albrektsson T., Johansson C. Osteoinduction, osteoconduction and osseointegration. 2001. Eur Spine J. 10:S96-S101.			
	C2	Dimmeler et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. 2001. Journal of Clin Invest. 108(3): 391-397.			
	C3	Rao et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. 1997. Proc. Natl. Acad. Sci. 96: 7797-7802.			
	C4	Steitz et al. Smooth Muscle Cell Phenotypic Transition Associated With Calcification: Upregulation of Cbfa1 and Downregulation of Smooth Muscle Lineage Markers. 2001. Circ. Res. 89:1147-1154			
	C5	Tintut et al. Multilineage Potential of Cells From the Artery Wall. 2003. Circulation. 108: 2505-2510			
	C6	Wada et al. Calcification of Vascular Smooth Muscle Cell Cultures : Inhibition by Osteopontin. 1999. Circ. Res. 8:166-178			
	C7	Wada et al. Lack of Positive Correlation Between Statin Use and Bone Mineral Density in Japanese Subjects With Type 2 Diabetes. 2000. Arch Intern Med. 160:2885			
	C8	Wang et al. Lipid Clearing Agents in Steroid-Induces Osteoporosis. 1995. J Formos Med Assoc. 94(10): 589-592.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Maria Leavitt/	Date Considered	06/22/2010
--------------------	-----------------	-----------------	------------

DC2/1098508

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.L./